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Deep learning to stratify lung nodules on annual follow-up CT
The main goal of lung cancer screening is to identify 
early-stage lung cancer while preventing unnecessary 
workup for benign nodules. The major source of error 
in early lung cancer detection and lung cancer screening 
is through radiological analysis. Findings of two large 
randomised controlled trials in high-risk populations 
(the National Lung Screening Trial [NLST]1 and the 
NELSON study2) have shown the positive effect of lung 
cancer screening by low-dose chest CT. With expected 
worldwide implementation of this screening method, 
the number of CT-detected lung nodules will increase 
greatly, because around half of people undergoing 
screening have at least one nodule.3 
In the USA, nodules detected at screening are managed 
according to the Lung CT Screening Reporting & Data 
System (Lung-RADS), which is based on diameter 
at first detection and the increase in diameter at 
follow-up. A proposed European protocol4 is based on 
nodule volume at first detection and a combination of 
volume and volume doubling time (VDT) at follow-up. 
To estimate baseline lung cancer risk, risk calculators 
are available.5 However, the probability of nodules 
detected at baseline being malignant differs from that 
of nodules detected at incidence screening. Baseline 
nodules might have been present for years whereas new 
nodules identified at incidence screening are relatively 
young and fast growing and possess a substantially 
higher cancer probability.6 For new nodules, temporal 
characteristics (ie, growth or change in density) will 
provide information about lung cancer risk rather than 
spatial (size) characteristics. Therefore, new nodules are 
managed differently from baseline nodules in established 
guidelines.1,4 In a lung cancer screening programme, 
a participant will receive one baseline screening, after 
which they will have up to 24 annual follow-up CTs. 
Therefore, accurate management of incident nodules 
will be crucial for the performance of screening, with 
more stringent volume threshold criteria.6
Machine learning techniques for clinicians’ 
support are augmenting 21st century health care 
with surprising force.7 In The Lancet Digital Health, 
Peng Huang and colleagues8 report a deep learning 
algorithm (termed DeepLR) for classification of screen-
detected lung nodules in follow-up imaging, and they 
validate DeepLR in a large external dataset. With the 
DeepLR algorithm, which is available online, Huang and 
colleagues claim to outperform Lung-RADS and stand-
alone diameter-based VDT for lung cancer prediction 
at follow-up CT, both in a training set (using data from 
NLST) and in a large external validation set. 
In a large-scale contribution to estimate lung cancer 
risk by deep learning based on images from subsequent 
CTs,9 lung cancer risk estimation was restricted to 1-year 
post CT. Thus, those findings cannot be used to identify 
individuals who might benefit from a longer screening 
interval. Huang and colleagues’ study adds value8 
because DeepLR can identify a low-risk group among 
their high-risk screening population who had only a 
0·2% chance to develop lung cancer in the next 3 years. 
These individuals might, therefore, benefit from repeat 
screening after 2 years, or even 3 years, rather than 
the current recommendation for 1-year screening. The 
study findings confirm that their deep learning method, 
which was trained on time-dependent characteristics, 
outperforms a diameter-based nodule protocol in terms 
of lung cancer detection sensitivity.
Before we begin using deep learning techniques as 
guidance for lung cancer risk estimation in clinical 
practice, it is important to realise the limitations. First, 
Huang and colleagues emphasise that DeepLR was 
trained using mainly baseline and annual screens from 
the NLST, but the performance of DeepLR on shorter 
or longer follow-up intervals is unknown. Second, VDT 
in Huang and colleagues’ study was calculated based 
on manual diameter measurements, which has been 
shown to be unreliable in a previous study,10 suggesting 
that VDT should be based on nodule volume alone. 
Furthermore, VDT should never be used as a stand-alone 
procedure, as was done by Huang and colleagues, but 
always in combination with a nodule volume cutoff.6 
Moreover, training of DeepLR was time-dependent and, 
therefore, included annual nodule growth rate, which is 
comparable with a nodule’s VDT. Thus, results for VDT 
in Huang and colleagues’ study may not reflect the true 
VDT value and findings cannot be translated into clinical 
practice.
What is the main message of Huang and colleagues’ 
study of deep learning in lung cancer nodule 
stratification? In follow-up imaging of a lung nodule, 
temporal changes provide valuable additional 
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information for lung cancer risk prediction to spatial 
characteristics, surpassing Lung-RADS. The time-
dependent training of DeepLR resulted in a very high 
true-negative nodule rate, potentially identifying 
individuals who might benefit from repeat screening 
in 2 or 3 years, compared with the current 1-year 
recommendation.
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